316 related articles for article (PubMed ID: 37345145)
1. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.
Pal D; Raj K; Nandi SS; Sinha S; Mishra A; Mondal A; Lagoa R; Burcher JT; Bishayee A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345145
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
3. HDAC Inhibitors in Acute Myeloid Leukemia.
San José-Enériz E; Gimenez-Camino N; Agirre X; Prosper F
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739588
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.
Manta A; Kazanas S; Karamaroudis S; Gogas H; Ziogas DC
Oncol Res; 2022; 30(5):211-219. PubMed ID: 37305348
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.
Sanaei M; Kavoosi F
Iran J Pharm Res; 2021; 20(3):324-336. PubMed ID: 34903992
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Quintás-Cardama A; Santos FP; Garcia-Manero G
Leukemia; 2011 Feb; 25(2):226-35. PubMed ID: 21116282
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Sanaei M; Kavoosi F
Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
[TBL] [Abstract][Full Text] [Related]
9. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
10. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma.
Zrimšek M; Kuchaříková H; Draganić K; Dobrovolná P; Heiss Spornberger V; Winkelmayer L; Hassler MR; Lochmanová G; Zdráhal Z; Egger G
Cells; 2022 Aug; 11(15):. PubMed ID: 35954222
[TBL] [Abstract][Full Text] [Related]
12. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.
Lyu X; Hu M; Peng J; Zhang X; Sanders YY
Ther Adv Chronic Dis; 2019; 10():2040622319862697. PubMed ID: 31367296
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.
Elmallah MIY; Micheau O
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248188
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Ververis K; Hiong A; Karagiannis TC; Licciardi PV
Biologics; 2013; 7():47-60. PubMed ID: 23459471
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
